Single chain antigen binding protein (sFv CC49): First human studies in colorectal carcinoma metastatic to liver

Cancer

Volumn 80, Issue 12 SUPPL., 1997, Pages 2458-2468

  Larson, Steven M ^a   El Shirbiny, Ayda M ^a   Divgi, Chaitanya R ^a   Sgouros, George ^a   Finn, Ronald D ^a   Tschmelitsch, Jorg ^d   Picon, Antonio ^a   Whitlow, Marc ^b   Schlom, Jeffrey ^c   Zhang, Jiaju ^a   Cohen, Alfred M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Enzon Incorporated   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Colorectal carcinoma; Intravenous injection; Liver; Metastatic; SFv CC49

Indexed keywords

IMMUNOGLOBULIN FRAGMENT; MONOCLONAL ANTIBODY CC49; MONOCLONAL ANTIBODY I 123;

ADULT; AGED; CANCER LOCALIZATION; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONFERENCE PAPER; DRUG CLEARANCE; DRUG UPTAKE; FEMALE; HUMAN; ISOTOPE LABELING; LIVER METASTASIS; MALE; PLASMA CLEARANCE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0031456426     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971215)80:12+<2458::aid-cncr17>3.0.co;2-b     Document Type: Conference Paper

References (14)

1. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee S-M, et al. Single-chain antigen-binding proteins. Science 1988;242:423-6.
2. Larson SM. Improved tumor targeting of a recombinant single-chain antigen-binding protein, [editorial]. J Natl Cancer Inst 1990;82(14):1173-4.
3. Begent RH, Verhaar MJ, Chester KA, Casey JL, Green AJ, Napier MP, et al. Clinical evidence of efficient tumor targeting based on sing-chain FV antibody selected from a combinatorial library. Nat Med 1996;2:979-84.
4. Colcher D, Horan Hand P, Nuti M, Schlom J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 1981;78:3199-203.
5. Larson SM. A model for others: a strategy for improving diagnosis and therapy of human malignancies using monoclonal antibodies targeting and TAG-72 oncofetal antigen [editorial]. Cancer Invest 1993;11(2):235-8.
6. Kostakoglu L, Divgi CR, Hilton S, Cordon-Cardo C, Scott AM, Kalaigian H, et al. Pre-selection of patients with high TAG-72 antigen expression leads to targeting of 94% of known metastatic tumor sites with monoclonal antibody I-131-CC49. Cancer Invest 1994;12(6):551-8.
7. Milenic DE, Yokota T, Filpula DR, et al. Construction, binding properties, metabolism, and tumor targeting of a single-chain sFv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 1991;51:6363-71.
8. Yokota T, Milenic DE, Whitlow M, et al. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain sFv and other immunoglobulin forms. Cancer Res 1993;53:3776-83.
9. Loevinger R, Buddinger TF, Watson EE. MIRD primer for absorbed dose calculations. 1st edition. New York: Society of Nuclear Medicine Press 1988.
10. Larson SM, Brown IP, Wright PW, Carrasquillo JA, Hellstrom I, Hellstrom KE. Imaging of melanoma with I-131-labeled monoclonal antibodies. J Nucl Med 1983;24:123-9.
11. Carrasquillo IA, Abrams PG, Schroff RW, Reynolds IC, Woodhouse CS, Morgan AC, et al. Effect of antibody dose on the imaging and biodistribution of Indium-111 9.2.27 anti-melanoma monoclonal antibody. J Nucl Med 1988;29:39-47.
12. Cohen AM, Minksy BD, Schilsky RL. Colon cancer. In: DeVita VT Jr., Hellman S, Rosenberg S, editors. Cancer: principles and practice of oncology. 4th edition. Philadelphia: J.B. Lippincott Co., 1993:938.
13. Yokoyama K, Carrasquillo JA, Chang AE, Colcher D, Roselli M, Sugarbaker P, et al. Differences in biodistribution of indium-111- and iodine-131-labeled B72.3 monoclonal antibodies in patients with colorectal cancer. J Nucl Med 1989;30:320-7.
14. Kobayashi H, Yoo TM, Kim IS, Kim M-K, Le N, Webber KO, et al. L-lysine effectively blocks renal uptake of I-125 and Tc-99m labeled anti-Tac difsulfide-stabilized sFv fragment. Cancer Res 1996;56:3788-95.